---
title: "AGEN: Secured $340M to advance Phase 3 BOT + BAL trial in MSS colon cancer, targeting major market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292478400.md"
description: "Up to $340 million in private placement will fund a pivotal Phase 3 trial of BOT + BAL in MSS colon cancer, targeting a $7B US market. The trial design is FDA-aligned, with interim data expected in 2027 and operations funded through 2031.Original document: Agenus Inc. [AGEN] Press release — Jul. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-13T11:04:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292478400.md)
  - [en](https://longbridge.com/en/news/292478400.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292478400.md)
generator: "portal-rs"
---

# AGEN: Secured $340M to advance Phase 3 BOT + BAL trial in MSS colon cancer, targeting major market

Up to $340 million in private placement will fund a pivotal Phase 3 trial of BOT + BAL in MSS colon cancer, targeting a $7B US market. The trial design is FDA-aligned, with interim data expected in 2027 and operations funded through 2031.

Original document: Agenus Inc. \[AGEN\] Press release — Jul. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [AGEN.US](https://longbridge.com/en/quote/AGEN.US.md)
- [00847G804.US](https://longbridge.com/en/quote/00847G804.US.md)

## Related News & Research

- [Agenus reports 21.2-month median survival in Phase 1b BOT+BAL study for MSS metastatic colorectal cancer](https://longbridge.com/en/news/297338792.md)
- [Agenus reports no recurrences in Phase 2 NEST trial of botensilimab plus balstilimab in resectable colon cancer](https://longbridge.com/en/news/297058971.md)
- [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md)
- [AI Winners, Victims, and the One Stock to Sell Now](https://longbridge.com/en/news/297431483.md)
- [Agenus posts investor deck spotlighting botensilimab-balstilimab neoadjuvant program in MSS colon cancer](https://longbridge.com/en/news/296536017.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**